[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@MACROVET888 MACROVET
MACROVET posts on X about $espr, $nams, $4578t, $4768t the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
Mentions: X #
- X Week XX +3.60%
- X Month XXX -XX%
Followers: XXX #
- X Week XXX -XXXX%
- X Month XXX -XXXX%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence finance countries stocks technology brands cryptocurrencies
Social topic influence $espr #2, $nams, $4578t, $4768t, has been, $3bn, $5bn, $mrk, money, printing
Top assets mentioned NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Merck & Co., Inc. (MRK) Bitcoin Incognito (XBI) 4 (4)
Top Social Posts #
Top posts by engagements in the last XX hours
"ESPR fits much better for BP in the CV space with much broader potential and a pipeline not even priced in. if $nams $3bn THEN yes $espr is a $5bn business with money printing from the global expansion. Should be no1 TGT for $mrk"
X Link @MACROVET888 2025-10-13T15:36Z XXX followers, XXX engagements
"The timing of $ESPR (Dated Oct.3 $3.30) in the public offering doc) strongly suggests it could be a defensive move to counter or complicate a rumored buyout offer from Otsuka America which some view as undervaluing the company's long-term potential despite the apparent premium"
X Link @MACROVET888 2025-10-07T23:48Z XXX followers, XXX engagements
"$ESPR $BIDU I have been a LT holder of Baidu. The Technical pattern was frustrating but this late summer with a huge compression of BB we assist to a brutal re-rating for this CN AI leader. ESPR is a different business but similar setup .brutal re-rating is coming for this SMID"
X Link @MACROVET888 2025-10-06T14:14Z XXX followers, 1423 engagements
"$ESPR $NAMS Phase X Specifics:The BROOKLYN trial (HeFH patients) explicitly reported no hsCRP difference from placebo at XX days (sustained to XXX days) confirming obicetrapib's lack of anti-inflammatory impact. BROADWAY (ASCVD/HeFH) and TANDEM (fixed-dose obicetrapib/ezetimibe"
X Link @MACROVET888 2025-10-13T15:27Z XXX followers, XXX engagements
"$ESPR $NAMS Obicetrapib+statins (NAMS)Phase 3: BROOKLYN/BROADWAY/TANDEM) MACE reduction in BROADWAY (21%) suggests potential CV benefits beyond lipids but not via hsCRP. CETP inhibitors like obicetrapib generally show neutral or slight hsCRP increases(10-15%) in broader pop"
X Link @MACROVET888 2025-10-13T15:21Z XXX followers, 1045 engagements
"$ESPR The cardiovascular M&A has been active with $verv sold for $1.3bn to LLY with zero drugs on phase III zero approved drugs and zero revenue. The technology is promising but then $ESPR is dramatically undervalued. Statins are a drug from the past"
X Link @MACROVET888 2025-09-25T12:50Z XXX followers, XXX engagements
"$ESPR $NAMS align with this with no hsCRP benefits noted in topline or presented data. These trials emphasize obicetrapib's lipid profile (e.g. Lp(a) reductions up to 57%) over inflammation"
X Link @MACROVET888 2025-10-13T15:27Z XXX followers, XXX engagements
"$espr $xbi The new uptrend is about to start $XXXX remains key before further strength. Lots of news around the corner. Just a pause the upper trend is now around $4"
X Link @MACROVET888 2025-10-13T14:11Z XXX followers, XXX engagements
"$ESPR $107m receivables $114m inventories for DSE tech transfer and Otsuka launch that will increase bottom line. and now $171m in cash .timing just before rumour and with an ATM broker's program of $51m. Down with offering and we fly"
X Link @MACROVET888 2025-10-08T12:47Z XXX followers, XXX engagements
"$ESPR good news todaythe selection of ESP-2001 appears driven by post-R&D Day optimization efforts. ESP-2001 is described as a "highly-specific allosteric ACLY inhibitor" discovered and refined using ESPR's ACLY expertise combined with Evotec's integrated drug disco. platform"
X Link @MACROVET888 2025-10-16T14:05Z XXX followers, XXX engagements
"$ESPR Esperion's bempedoic acid outperforms NAMS in demonstrated hsCRP lowering potentially enhancing CV event reduction beyond lipids (e.g. XX% MACE risk reduction in CLEAR). Obicetrapib excels in Lp(a) and LDL-C but leaves inflammation unaddressed"
X Link @MACROVET888 2025-10-13T15:32Z XXX followers, XXX engagements
"$espr The turnaround has been engaged since the capital structure re-structured last year they know the US market will be tougher and show with global partnership that the drug is the future and sales are growing fast in E.U and soon Japan"
X Link @MACROVET888 2025-10-09T15:20Z XXX followers, XXX engagements